zika virus vlp

Creative Biostructure develops a safe, effective and straightforward strategy to rapidly produce a Zika vaccine. Our Zika Virus VLPs are composed of partially mature particles containing Envelope (E), pre-Membrane (prM) and Membrane (M). VLPs are produced in mammalian suspension cell cultures offering a suitable system for rapid scale up of manufacturing, without the risk of working with an infectious agent. The lack of infectivity of the product eliminates the need for chemical inactivation, which may compromise vaccine efficacy and safety. The particulate nature of the vaccine and the preservation of a variety of conformational antigenic sites may even render this vaccine efficacious in humans without using adjuvant if its incorporation into a vaccine raises safety concerns. In summary, the Zika VLP platform puts forward a vaccine composition and production system ready for clinical development of a safe and effective prophylactic Zika vaccine, which is greatly needed to meet the challenges imposed by the spread of the Zika epidemic.

		From	To	From	To	From	To
Monday	Open
Tuesday	Open
Wednesday	Open
Thursday	Open
Friday	Open
Saturday	Open
Sunday	Open